...KRAS2 exon 2).,All 26 pts were evaluated for response and toxicity. There were 0 CRs, 1 PR (response duration = 5 months...
...KRAS mutations, response to TKI, and survival and correlated these findings with histology as above.,NSCLC were classifi...
...KRAS+ (HR = 1.07, 95% CI: 1.00-1.15) and BRAF-/KRAS- (HR = 1.05, 95% CI: 1.00-1.11) but not BRAF+ tumors (HR = 0.89, 95%...
...KRAS populations. A better understanding of mechanisms of action of drugs, tumor biology, and predictive biomarkers are ...
...KRAS wild-type normal pancreas cells, as well as in KRAS mutated pancreatic cancer cells and was essential for ER homoeo...
...KRas. Consistent with this, we found that ectopic expression of oncogenic KRas and HRas in cells resulted in elevated CI...
...KRAS mutations in ccfDNA from metastatic colorectal cancer patients by E-ice-COLD-PCR with two digital PCR approaches. F...
...KRAS mutation, without the presence of BRAF Accordingly, the addition of MEK-inhibiting trametinib to BRAF-inhibiting da...
...Kras-driven pancreatic cancer progression, is currently unclear. Here we show that disruption of paracrine Hedgehog sign...
KRAS mutations are an established predictor of lack of response to EGFR-targeted therapies in patients with metastatic c...
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话: 0531-88819269